Altimmune (ALT) Stock
Clinical stage biotech developing vaccines and treatments. Here's the price, business snapshot, and what's worth knowing about Altimmune in August 2026.
Altimmune Inc (ALT) is a clinical-stage biotechnology company focused on developing immunotherapies and vaccine candidates. As a small-cap business (market cap ~ $356.6M), it primarily derives value from its pipeline and clinical progress rather than steady revenue. Investors should know the stock is catalyst-driven: trial readouts, regulatory decisions and partner deals can produce significant share-price moves. That creates opportunity but also considerable risk — early-stage programmes are binary and timelines can be lengthy. Financial resources, partnerships and trial outcomes will shape valuation and dilution risk. This summary is general information for educational purposes and not personalised investment advice; suitability depends on your goals, risk tolerance and time horizon. Past performance is not indicative of future results and returns are not guaranteed.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Altimmune's stock with a target price of $20.15, indicating strong growth potential.
Financial Health
Altimmune Inc has minimal revenue and low financial indicators, suggesting financial challenges ahead.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring ALT
Liver Disease Therapies | Next-Gen FDA Approvals
The FDA's recent accelerated approval of Gilead's Hepcludex has established the first legal treatment for a deadly liver infection known as hepatitis D. This milestone opens the door for investors to explore opportunities in companies developing innovative liver disease therapies, specialized diagnostics, and advanced patient monitoring systems.
Published: 26 May 2026
Explore BasketNext-Gen Hepatic Therapeutics | Basket Overview
The FDA has granted Gilead Sciences approval for the first-ever treatment targeting chronic hepatitis delta virus. This landmark regulatory decision paves the way for further investments in biotechnology companies developing novel therapeutics for rare and complex liver diseases.
Published: 24 May 2026
Explore BasketObesity Drug Distribution via Telehealth Platforms Explained
Novo Nordisk has launched a discounted telehealth subscription model for its popular Wegovy treatments to counter rising competition. This shift creates compelling investment opportunities in the digital health platforms that are becoming vital distribution channels for blockbuster obesity drugs.
Published: 1 April 2026
Explore BasketOral Obesity Treatments: Investment Theme Explained
Novo Nordisk has launched the first oral GLP-1 weight loss medication, Wegovy, representing a major evolution in the obesity treatment landscape. This shift from injections to pills creates an investment opportunity in pharmaceutical innovators and the digital health companies enabling broad access.
Published: 6 January 2026
Explore BasketObesity Drug Stocks: Medicare Coverage Trade-offs
A new agreement between the Trump administration, Eli Lilly, and Novo Nordisk will dramatically lower the cost of GLP-1 weight loss drugs and expand Medicare coverage. This move is expected to significantly increase patient access and boost sales, creating opportunities for the drug manufacturers and their key suppliers.
Published: 7 November 2025
Explore BasketBiotech Buyout Wave Targets Obesity Market 2025
Pfizer's bid for obesity drug maker Metsera has turned into a legal battle after a counteroffer from Novo Nordisk, highlighting the fierce competition in the weight-loss market. This intense M&A activity signals that other biotech companies with promising obesity treatments could become the next valuable acquisition targets.
Published: 1 November 2025
Explore BasketWeight-Loss Drug M&A: Valuation Risk Concerns
Novo Nordisk's superior bid for Metsera has ignited a bidding war with Pfizer, highlighting the intense M&A activity in the obesity drug market. This theme focuses on other biotech companies with promising weight-loss therapies that could become the next acquisition targets.
Published: 31 October 2025
Explore BasketOzempic Price Pressure | Pharma Investment Shift
A recent announcement of plans to slash prices for major weight-loss drugs has created turmoil for market leaders Novo Nordisk and Eli Lilly. This theme explores the investment opportunities that arise for competing pharmaceutical companies and developers of alternative treatments who may benefit from this market disruption.
Published: 21 October 2025
Explore BasketWeight-Loss Drug Shakeup: What's Next for Biotechs?
Following former President Trump's pledge to slash prices for popular weight-loss drugs, uncertainty has hit major pharmaceutical stocks. This theme identifies competitor firms and biotechs that could gain an edge as the pricing landscape for metabolic drugs shifts.
Published: 18 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
Catalyst-driven upside
Trial readouts and regulatory milestones can create sharp share-price moves; however, outcomes are binary and performance can vary.
Early-stage pipeline
An early-stage programme offers potential if trials succeed, but carries higher scientific and regulatory risk and possible dilution.
Partnerships matter
Collaborations or licensing deals can de-risk programmes and provide funding, yet they are not guaranteed and may take time to materialise.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
